GlaxoSmithKline (GSK) has been granted EU approval of its adjuvanted cervical cancer vaccine Cervarix, and is confident that the jab can challenge the likes of Merck's high-profile Gardasil.The vaccine has been approved for the prevention of pre-cancerous cervical lesions and cervical cancer causally related to human papillomavirus (HPV) (types 16 and 18), and formulated with GSK's novel AS04 adjuvant system is said to offer broad, extended protection to women given the jab.
DrugResearcher.com September 25, 2007
Tuesday, October 2, 2007
Another New Unnecessary Vaccine -- Who Loses?
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment